Results 31 to 40 of about 546 (157)

Serious adverse events with tedizolid and linezolid: pharmacovigilance insights through the FDA adverse event reporting system

, 2021
Background To investigate the adverse event (AE) profile of tedizolid and linezolid in post-marketing surveillance. Research design and methods We queried the worldwide FDA Adverse Event Reporting System and selected all records where tedizolid and ...
Fusaroli M., De Ponti F., Gatti M., Moretti U., Poluzzi E., Raschi E.   +5 more
core   +2 more sources

In Vitro Activities of Ceftobiprole, Dalbavancin, Tedizolid and Comparators against Clinical Isolates of Methicillin-Resistant Staphylococcus aureus Associated with Skin and Soft Tissue Infections

Antibiotics, 2023
Skin and soft tissue infections (SSTIs) are associated with significant morbidity and healthcare costs, especially when caused by methicillin-resistant Staphylococcus aureus (MRSA).
Sofia Maraki, Viktoria Eirini Mavromanolaki, Dimitra Stafylaki, Evangelia Iliaki-Giannakoudaki, George Hamilos   +4 more
doaj   +1 more source

Monitoring Salivary Concentrations of Tedizolid and Linezolid Using Rats

, 2023
Background and ObjectiveTherapeutic drug monitoring (TDM) is an effective tool for the management of patients who are administered linezolid. The use of saliva for TDM has potential advantages over the use of plasma; however, only a few reports have ...
Shunsuke Nashimoto, Takekuma, Yoh, Mitsuru Sugawara, Yoh Takekuma, Nashimoto, Shunsuke, Hitoshi Kashiwagi, Kashiwagi, Hitoshi, Yuki Inoue, Yuki Sato, Inoue, Yuki, Sato, Yuki, Sugawara, Mitsuru   +11 more
core   +1 more source

Tedizolid, Faropenem, and Moxifloxacin Combination With Potential Activity Against Nonreplicating Mycobacterium tuberculosis

Frontiers in Pharmacology, 2021
Background:Mycobacteriumtuberculosis [Mtb] could be present in different metabolic population in the lung lesions, and nonreplicating persisters [NRP], associated with latent tuberculosis [TB], are the most difficult to kill.Objective: Test the ...
Shashikant Srivastava, Shashikant Srivastava, Shashikant Srivastava, Kayle N. Cirrincione, Devyani Deshpande, Tawanda Gumbo, Tawanda Gumbo, Tawanda Gumbo   +7 more
doaj   +1 more source

Retrospective Real-World Evaluation of Outcomes in Patients with Skin and Soft Structure Infections Treated with Tedizolid in an Outpatient Setting

Infectious Diseases and Therapy, 2020
Introduction Outcomes data for patients who received tedizolid for acute bacterial skin and skin-structure infections (ABSSSIs) are scant. We provide a real-world analysis of economic and clinical outcomes following tedizolid use in the outpatient ...
Ravina Kullar, Laura A. Puzniak, Jason P. Swindle, Thomas Lodise   +3 more
doaj   +1 more source

In vitro activity of Tedizolid and Dalbavancin against MRSA strains is dependent on infection source

International Journal of Infectious Diseases, 2019
Objective: We tested the in vitro susceptibility to Tedizolid and Dalbavancin of Methicillin-resistant Staphylococcus aureus strains recovered from blood and wound cultures, and compared our results with studies conducted in the last four years.
Maya Azrad, Motti Baum, Assaf Rokney, Yish Levi, Avi Peretz   +4 more
doaj   +1 more source

The Sterilizing Effect of Intermittent Tedizolid for Pulmonary Tuberculosis [PDF]

Clinical Infectious Diseases, 2018
Linezolid exhibits remarkable sterilizing effect in tuberculosis; however, a large proportion of patients develop serious adverse events. The congener tedizolid could have a better side-effect profile, but its sterilizing effect potential is unknown.We performed a 42-day tedizolid exposure-effect and dose-fractionation study in the hollow fiber system ...
Shashikant Srivastava, Devyani Deshpande, Eric Nuermberger, Pooi S Lee, Kayle Cirrincione, Keertan Dheda, Tawanda Gumbo   +6 more
openaire   +2 more sources

New and old oxazolidinones: tedizolid vs. linezolid [PDF]

Клиническая микробиология и антимикробная химиотерапия, 2017
Tedizolid is a novel oxazolidinone that has been recently approved for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) caused by Gram-positive pathogens, including MRSA.
Dekhnich A.V., Hachatryan N.N.
doaj  

Nonclinical and pharmacokinetic assessments to evaluate the potential of tedizolid and linezolid to affect mitochondrial function [PDF]

, 2015
Prolonged treatment with the oxazolidinone linezolid is associated with myelosuppression, lactic acidosis, and neuropathies, toxicities likely caused by impairment of mitochondrial protein synthesis (MPS).
Radovsky, Ann, Prokocimer, Philippe, Flanagan, Shawn, Das, Debaditya, Fiedler-Kelly, Jill, McKee, Edward E, Passarell, Julie, Tulkens, Paul M., Hosako, Hiromi   +8 more
core   +1 more source

Pharmacokinetics of Tedizolid in Subjects with Renal or Hepatic Impairment [PDF]

Antimicrobial Agents and Chemotherapy, 2014
ABSTRACT Two open-label, single-dose, parallel-group studies were conducted to characterize the pharmacokinetics of the novel antibacterial tedizolid and the safety of tedizolid phosphate, its prodrug, in renally or hepatically impaired subjects.
S, Flanagan, S L, Minassian, D, Morris, R, Ponnuraj, T C, Marbury, H W, Alcorn, E, Fang, P, Prokocimer   +7 more
openaire   +2 more sources